Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Among authors: woodworth t. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. Haringman JJ, et al. Among authors: woodworth t. Arthritis Rheum. 2006 Aug;54(8):2387-92. doi: 10.1002/art.21975. Arthritis Rheum. 2006. PMID: 16869001 Free article. Clinical Trial.
Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
Garnero P, Thompson E, Woodworth T, Smolen JS. Garnero P, et al. Among authors: woodworth t. Arthritis Rheum. 2010 Jan;62(1):33-43. doi: 10.1002/art.25053. Arthritis Rheum. 2010. PMID: 20039425 Free article. Clinical Trial.
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.
Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, Christiansen C, Schubert T, Qvist P, Schett G, Platt A, Bay-Jensen AC. Karsdal MA, et al. Among authors: woodworth t. Arthritis Res Ther. 2011 Apr 28;13(2):215. doi: 10.1186/ar3280. Arthritis Res Ther. 2011. PMID: 21539724 Free PMC article. Review.
Health status response of rheumatoid arthritis to treatment with DAB486IL-2.
Anderson JJ, O'Neill A, Woodworth T, Haddad J, Sewell KL, Moreland LW. Anderson JJ, et al. Among authors: woodworth t. Arthritis Care Res. 1996 Apr;9(2):112-9. doi: 10.1002/1529-0131(199604)9:2<112::aid-anr1790090207>3.0.co;2-x. Arthritis Care Res. 1996. PMID: 8970269 Clinical Trial.
118 results